Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 2
2007 3
2011 1
2014 2
2018 2
2019 1
2020 1
2021 2
2022 2
2023 3
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators. Cho BC, et al. N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26. N Engl J Med. 2024. PMID: 38924756 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK. Sangro B, et al. Among authors: charoentum c. J Clin Oncol. 2024 Aug 10;42(23):2790-2799. doi: 10.1200/JCO.23.01462. Epub 2024 May 28. J Clin Oncol. 2024. PMID: 38805668 Free PMC article. Clinical Trial.
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn JB, Bello M, Charoentum C, Chen LT, de Lima Lopes G Jr, Ho GF, Kong HL, Lam KO, Liu TS, Park YS, Sriuranpong V, Sudoyo AW, Wang JY, Zhang J, Zhang SZ, Ciardiello F, Köhne CH, Shaw M, Kim TW. Cheng AL, et al. Among authors: charoentum c. Clin Colorectal Cancer. 2014 Sep;13(3):145-55. doi: 10.1016/j.clcc.2014.06.004. Epub 2014 Jun 26. Clin Colorectal Cancer. 2014. PMID: 25209093
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.
Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, Coward J, Fourie S, Kurochkin A, Malan DR, Mant A, Sharma V, Shue H, Tazbirkova A, Berciano-Guerrero MA, Charoentum C, Dalle S, Dechaphunkul A, Dudnichenko O, Koralewski P, Lugowska I, Montaudié H, Muñoz-Couselo E, Sriuranpong V, Oliviero J, Desai J. Clingan P, et al. Among authors: charoentum c. J Immunother Cancer. 2023 Oct;11(10):e007637. doi: 10.1136/jitc-2023-007637. J Immunother Cancer. 2023. PMID: 37848259 Free PMC article.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer.
Chen LT, Vogel A, Hsu C, Chen MH, Fang W, Pangarsa EA, Sharma A, Ikeda M, Park JO, Tan CK, Regala E, Tai D, Tanasanvimon S, Charoentum C, Chee CE, Lui A, Sow J, Oh DY, Ueno M, Ramaswamy A, Jeo WS, Zhou J, Curigliano G, Yoshino T, Bai LY, Pentheroudakis G, Chiang NJ, Cervantes A, Chen JS, Ducreux M. Chen LT, et al. Among authors: charoentum c. ESMO Open. 2024 Aug;9(8):103647. doi: 10.1016/j.esmoop.2024.103647. Epub 2024 Aug 6. ESMO Open. 2024. PMID: 39232586 Free PMC article.
Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study.
Luangnara A, Kiratikanon S, Ketpueak T, Suksombooncharoen T, Charoentum C, Chewaskulyong B, Tovanabutra N, Chiewchanvit S, Nochaiwong S, Chuamanochan M. Luangnara A, et al. Among authors: charoentum c. Front Immunol. 2022 Oct 20;13:965550. doi: 10.3389/fimmu.2022.965550. eCollection 2022. Front Immunol. 2022. PMID: 36341419 Free PMC article.
30 results